Program
XOI Low Dose
Also written as “XOI High Dose”.
Its studies are mostly in Arthritis, Gouty, led by Swedish Orphan Biovitrum.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Swedish Orphan Biovitrum | 11 open or running | phase 2since Aug 7, 2025 | Aug 7, 2025 | Nov 2026phase 2 · NCT07116746 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2025First study: phase 2 study in GoutFirst studyNCT07116746 · 15 enrolled · United States
Ahead
- Nov 2026Primary completion: phase 2 study in GoutNCT07116746
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07116746Gout · United States | 2 | Active, not recruiting | Nov 2026 | 15 |
How it is read
Names in the registry
- “XOI Low Dose”, 1 entry
- “XOI High Dose”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Gouty, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.